Skip to main content
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

view all Clinical Trials

Overview

RETHINC is a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily in symptomatic current and former smokers with respiratory symptoms despite preserved spirometry as defined by CAT ≥ 10 and post-bronchodilator FEV1/FVC ratio ≥0.70, respectively.

Contact

For more information about this trial or to inquire about eligibility, email breathe@temple.edu or call 215-707-1359.